Cargando…

Erratum to “Low Baseline Interleukin-17A Levels Are Associated with Better Treatment Response at 12 Weeks to Tocilizumab Therapy in Rheumatoid Arthritis Patients”

Detalles Bibliográficos
Autores principales: Lee, Sang Jin, Park, Won, Park, Sung Hwan, Shim, Seung-Cheol, Baek, Han Joo, Yoo, Dae-Hyun, Kim, Hyun Ah, Lee, Soo Kon, Lee, Yun Jong, Park, Young Eun, Cha, Hoon-Suk, Park, Jin Kyun, Lee, Eun Young, Lee, Eun Bong, Song, Yeong Wook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585674/
https://www.ncbi.nlm.nih.gov/pubmed/28913368
http://dx.doi.org/10.1155/2017/7869412
_version_ 1783261680595107840
author Lee, Sang Jin
Park, Won
Park, Sung Hwan
Shim, Seung-Cheol
Baek, Han Joo
Yoo, Dae-Hyun
Kim, Hyun Ah
Lee, Soo Kon
Lee, Yun Jong
Park, Young Eun
Cha, Hoon-Suk
Park, Jin Kyun
Lee, Eun Young
Lee, Eun Bong
Song, Yeong Wook
author_facet Lee, Sang Jin
Park, Won
Park, Sung Hwan
Shim, Seung-Cheol
Baek, Han Joo
Yoo, Dae-Hyun
Kim, Hyun Ah
Lee, Soo Kon
Lee, Yun Jong
Park, Young Eun
Cha, Hoon-Suk
Park, Jin Kyun
Lee, Eun Young
Lee, Eun Bong
Song, Yeong Wook
author_sort Lee, Sang Jin
collection PubMed
description
format Online
Article
Text
id pubmed-5585674
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-55856742017-09-14 Erratum to “Low Baseline Interleukin-17A Levels Are Associated with Better Treatment Response at 12 Weeks to Tocilizumab Therapy in Rheumatoid Arthritis Patients” Lee, Sang Jin Park, Won Park, Sung Hwan Shim, Seung-Cheol Baek, Han Joo Yoo, Dae-Hyun Kim, Hyun Ah Lee, Soo Kon Lee, Yun Jong Park, Young Eun Cha, Hoon-Suk Park, Jin Kyun Lee, Eun Young Lee, Eun Bong Song, Yeong Wook J Immunol Res Erratum Hindawi 2017 2017-08-20 /pmc/articles/PMC5585674/ /pubmed/28913368 http://dx.doi.org/10.1155/2017/7869412 Text en Copyright © 2017 Sang Jin Lee et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Erratum
Lee, Sang Jin
Park, Won
Park, Sung Hwan
Shim, Seung-Cheol
Baek, Han Joo
Yoo, Dae-Hyun
Kim, Hyun Ah
Lee, Soo Kon
Lee, Yun Jong
Park, Young Eun
Cha, Hoon-Suk
Park, Jin Kyun
Lee, Eun Young
Lee, Eun Bong
Song, Yeong Wook
Erratum to “Low Baseline Interleukin-17A Levels Are Associated with Better Treatment Response at 12 Weeks to Tocilizumab Therapy in Rheumatoid Arthritis Patients”
title Erratum to “Low Baseline Interleukin-17A Levels Are Associated with Better Treatment Response at 12 Weeks to Tocilizumab Therapy in Rheumatoid Arthritis Patients”
title_full Erratum to “Low Baseline Interleukin-17A Levels Are Associated with Better Treatment Response at 12 Weeks to Tocilizumab Therapy in Rheumatoid Arthritis Patients”
title_fullStr Erratum to “Low Baseline Interleukin-17A Levels Are Associated with Better Treatment Response at 12 Weeks to Tocilizumab Therapy in Rheumatoid Arthritis Patients”
title_full_unstemmed Erratum to “Low Baseline Interleukin-17A Levels Are Associated with Better Treatment Response at 12 Weeks to Tocilizumab Therapy in Rheumatoid Arthritis Patients”
title_short Erratum to “Low Baseline Interleukin-17A Levels Are Associated with Better Treatment Response at 12 Weeks to Tocilizumab Therapy in Rheumatoid Arthritis Patients”
title_sort erratum to “low baseline interleukin-17a levels are associated with better treatment response at 12 weeks to tocilizumab therapy in rheumatoid arthritis patients”
topic Erratum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585674/
https://www.ncbi.nlm.nih.gov/pubmed/28913368
http://dx.doi.org/10.1155/2017/7869412
work_keys_str_mv AT leesangjin erratumtolowbaselineinterleukin17alevelsareassociatedwithbettertreatmentresponseat12weekstotocilizumabtherapyinrheumatoidarthritispatients
AT parkwon erratumtolowbaselineinterleukin17alevelsareassociatedwithbettertreatmentresponseat12weekstotocilizumabtherapyinrheumatoidarthritispatients
AT parksunghwan erratumtolowbaselineinterleukin17alevelsareassociatedwithbettertreatmentresponseat12weekstotocilizumabtherapyinrheumatoidarthritispatients
AT shimseungcheol erratumtolowbaselineinterleukin17alevelsareassociatedwithbettertreatmentresponseat12weekstotocilizumabtherapyinrheumatoidarthritispatients
AT baekhanjoo erratumtolowbaselineinterleukin17alevelsareassociatedwithbettertreatmentresponseat12weekstotocilizumabtherapyinrheumatoidarthritispatients
AT yoodaehyun erratumtolowbaselineinterleukin17alevelsareassociatedwithbettertreatmentresponseat12weekstotocilizumabtherapyinrheumatoidarthritispatients
AT kimhyunah erratumtolowbaselineinterleukin17alevelsareassociatedwithbettertreatmentresponseat12weekstotocilizumabtherapyinrheumatoidarthritispatients
AT leesookon erratumtolowbaselineinterleukin17alevelsareassociatedwithbettertreatmentresponseat12weekstotocilizumabtherapyinrheumatoidarthritispatients
AT leeyunjong erratumtolowbaselineinterleukin17alevelsareassociatedwithbettertreatmentresponseat12weekstotocilizumabtherapyinrheumatoidarthritispatients
AT parkyoungeun erratumtolowbaselineinterleukin17alevelsareassociatedwithbettertreatmentresponseat12weekstotocilizumabtherapyinrheumatoidarthritispatients
AT chahoonsuk erratumtolowbaselineinterleukin17alevelsareassociatedwithbettertreatmentresponseat12weekstotocilizumabtherapyinrheumatoidarthritispatients
AT parkjinkyun erratumtolowbaselineinterleukin17alevelsareassociatedwithbettertreatmentresponseat12weekstotocilizumabtherapyinrheumatoidarthritispatients
AT leeeunyoung erratumtolowbaselineinterleukin17alevelsareassociatedwithbettertreatmentresponseat12weekstotocilizumabtherapyinrheumatoidarthritispatients
AT leeeunbong erratumtolowbaselineinterleukin17alevelsareassociatedwithbettertreatmentresponseat12weekstotocilizumabtherapyinrheumatoidarthritispatients
AT songyeongwook erratumtolowbaselineinterleukin17alevelsareassociatedwithbettertreatmentresponseat12weekstotocilizumabtherapyinrheumatoidarthritispatients